Seattle Genetics, Inc. will receive a $5 million milestone payment under its Adcetris (brentuximab vedotin) collaboration with Takeda Pharmaceutical Co., triggered by Takeda’s annual sales surpassing $100 million in its territories. The milestone will be recognized as royalty revenue in 1Q14.   “This sales milestone, along with the recent approvals of Adcetris in Japan, Singapore and Australia, illustrate the strong commercial and regulatory progress being made by Takeda in its territories,” sai...